A detailed history of Triumph Capital Management transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Triumph Capital Management holds 20,195 shares of BMY stock, worth $945,327. This represents 0.25% of its overall portfolio holdings.

Number of Shares
20,195
Previous 12,399 62.88%
Holding current value
$945,327
Previous $573,000 58.81%
% of portfolio
0.25%
Previous 0.19%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$43.31 - $48.98 $337,644 - $381,848
7,796 Added 62.88%
20,195 $910,000
Q2 2025

Jul 09, 2025

SELL
$44.12 - $59.6 $610,091 - $824,148
-13,828 Reduced 52.72%
12,399 $573,000
Q1 2025

May 06, 2025

BUY
$53.9 - $63.11 $1.12 Million - $1.31 Million
20,715 Added 375.82%
26,227 $1.6 Million
Q4 2024

Feb 14, 2025

SELL
$51.92 - $59.94 $9,449 - $10,909
-182 Reduced 3.2%
5,512 $311,000
Q3 2024

Feb 14, 2025

SELL
$39.66 - $51.75 $409,767 - $534,681
-10,332 Reduced 64.47%
5,694 $294,000
Q2 2024

Feb 14, 2025

BUY
$40.25 - $52.99 $75,066 - $98,826
1,865 Added 13.17%
16,026 $665,000
Q1 2024

Apr 25, 2024

BUY
$47.98 - $54.4 $17,944 - $20,345
374 Added 2.71%
14,161 $767,000
Q4 2023

Feb 05, 2024

BUY
$48.48 - $57.85 $417,170 - $497,799
8,605 Added 166.06%
13,787 $707,000
Q3 2023

Oct 31, 2023

BUY
$57.89 - $64.73 $84,750 - $94,764
1,464 Added 39.38%
5,182 $300,000
Q2 2023

Aug 03, 2023

BUY
$63.71 - $70.74 $236,873 - $263,011
3,718 New
3,718 $237,000
Q3 2021

Nov 15, 2021

BUY
$59.17 - $69.31 $372,830 - $436,722
6,301 New
6,301 $378,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $99.5B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Triumph Capital Management Portfolio

Follow Triumph Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Triumph Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Triumph Capital Management with notifications on news.